Bayer to buy Perfuse Therapeutics for $300M upfront
拜耳以3亿美元预付款收购Perfuse Therapeutics

Bayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness.
拜耳承诺先期支付3亿美元，收购眼科生物技术公司Perfuse Therapeutics及其针对主要致盲原因的中期临床项目。